Andrew K. Godwin

Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors.

Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium.

Telomere length changes in human cancer.

OVCA2 is downregulated and degraded during retinoid-induced apoptosis.

Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity.

Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations.

Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways.

Elevated JNK activation contributes to the pathogenesis of human brain tumors.

Ras/MAPK pathway confers basement membrane dependence upon endoderm differentiation of embryonic carcinoma cells.

DNA array-based method for detection of large rearrangements in the BRCA1 gene.

Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis.

Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.

Microarrays in cancer: research and applications.

Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.

Expression of constitutively activated EGFRvIII in non-small cell lung cancer.

Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27.

Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.

Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis.

The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene.

Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair.

Altered expression of the septin gene, SEPT9, in ovarian neoplasia.

Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies.

Focus on epithelial ovarian cancer.

Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk.

Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1.

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.

Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer.

Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations.

Linking transcriptional elongation and messenger RNA export to metastatic breast cancers.

Familial cancer associated with a polymorphism in ARLTS1.

Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.

WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome.

Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells.

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.

Enhanced counseling for women undergoing BRCA1/2 testing: impact on subsequent decision making about risk reduction behaviors.

Perception of differentiation cues by GATA factors in primitive endoderm lineage determination of mouse embryonic stem cells.

Molecular research directions in the management of gastrointestinal stromal tumors.

The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.

Mass spectrometric identification of serine hydrolase OVCA2 in the medulloblastoma cell line DAOY.

The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.

BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance.

Molecular genetic evidence that endometriosis is a precursor of ovarian cancer.

White spot syndrome virus open reading frame 222 encodes a viral E3 ligase and mediates degradation of a host tumor suppressor via ubiquitination.

Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.

Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations.

BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation.

Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.

No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years.

Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility.

BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.

Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer.

The molecular pathogenesis of gastrointestinal stromal tumors.

Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis.

Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors.

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.

Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.

AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.

Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer.

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.

Prostate cancer risk assessment program: a 10-year update of cancer detection.

Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis.

Ovca1, a candidate gene of the genetic modifier of Tp53, Mop2, affects mouse embryonic lethality.

Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk.

Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.

The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium.

Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia.

Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner.

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.

BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.

The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors.

Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis.

Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.

No evidence that GATA3 rs570613 SNP modifies breast cancer risk.

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.

Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries.

Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer.

Biological significance of prolactin in gynecologic cancers.

Clinical and molecular characteristics of gastrointestinal stromal tumors in the pediatric and young adult population.

GATA6 &#x7684;&#x635F;&#x5931;&#x4F1A;&#x5BFC;&#x81F4;&#x6838;&#x53D8;&#x5F62;&#x548C;&#x975E;&#x6574;&#x500D;&#x4F53;&#x5728;&#x5375;&#x5DE2;&#x764C;&#x3002;

High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors.

Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia.

Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.

Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing.

Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk.

Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.

Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition.

Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.

Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data.

Subtypes of familial breast tumours revealed by expression and copy number profiling.

Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations.

Frequent downregulation of miR-34 family in human ovarian cancers.

Nuclear entry of activated MAPK is restricted in primary ovarian and mammary epithelial cells.

LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer.

FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.

Anti-human embryonic stem cell monoclonal antibody Hesca-2 binds to a glycan epitope commonly found on carcinomas.

Role of gamma-synuclein in microtubule regulation.

Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer.

Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.

Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.

Alteration of Differentiation Potentials by Modulating GATA Transcription Factors in Murine Embryonic Stem Cells.

Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.

Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.

Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

Novel glycan biomarkers for the detection of lung cancer.

A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.

Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

Nuclear envelope structural defects cause chromosomal numerical instability and aneuploidy in ovarian cancer.

Exploring the link between MORF4L1 and risk of breast cancer.

Expression of Siglec-11 by human and chimpanzee ovarian stromal cells, with uniquely human ligands: implications for human ovarian physiology and pathology.

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.

Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion.

A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility.

Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.

Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.

Novel surface targets and serum biomarkers from the ovarian cancer vasculature.

Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer.

Serum antimüllerian hormone in healthy premenopausal women.

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence.

Common breast cancer susceptibility loci are associated with triple-negative breast cancer.

Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

Predisposition to cancer caused by genetic and functional defects of mammalian Atad5.

An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study.

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.

Bench to bedside and back again: personalizing treatment for patients with GIST.

Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma.

19p13.1 is a triple negative-specific breast cancer susceptibility locus.